BridgeBio Pharma
BBIO
220 hedge funds and large institutions have $4.24B invested in BridgeBio Pharma in 2023 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 66 increasing their positions, 74 reducing their positions, and 27 closing their positions.
100% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 27
65% more capital invested
Capital invested by funds: $2.58B → $4.24B (+$1.67B)
57% more call options, than puts
Call options by funds: $91.1M | Put options by funds: $58M
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
12% more funds holding
Funds holding: 196 → 220 (+24)
5.82% more ownership
Funds ownership: 93.34% → 99.16% (+5.8%)
11% less repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$72.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$40.3M |
| 3 |
Janus Henderson Group
London,
|
+$31.2M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$31.2M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$28.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$57.6M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$42.6M |
| 3 |
AIG
American International Group
New York
|
-$26.1M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$12.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$11.6M |
BBIO Hedge Fund Activity: Q3 2023 in Review
220 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2023, worth a combined $4.24B — up 65% from $2.58B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new BBIO positions and 27 closed out — a net gain of 27 holders — while 66 added to existing stakes and 74 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $72.7M. The largest seller was State Street, cutting an estimated $57.6M.
- 220 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2023, up from 196 in Q2 2023.
- Funds reported $4.24B of BridgeBio Pharma stock for Q3 2023, up 65% quarter-over-quarter.
- 54 funds opened new BridgeBio Pharma positions in Q3 2023 and 27 closed out, a net change of +27 holders.
- The largest BridgeBio Pharma buyer in Q3 2023 was AllianceBernstein, an estimated $72.7M added.
- The largest BridgeBio Pharma seller in Q3 2023 was State Street, an estimated $57.6M sold.
Based on aggregated 13F filings for Q3 2023.